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From a typical focal nodular
hyperplasia to a ﬁbrotic band
with capsular retraction: A case
report
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Spontaneous  regression
Figure 1. Line A. First MR examination (2006), showing two hyper vascular lesions (lesion 1 and 2), developed in a non-dysmorphic,
non-fatty liver and localized in segment IV, slightly hyperintense on T2-weighted sequence, with intense enhancement at the arterial phase
without wash-out. All these ﬁndings were consistent with typical FNHs. Line B. Second MR examination (2009), showing a reduction size of
Observation
A  42-year-old  woman  had  a  history  of  fortuitously  discovered
liver  lesions  detected  during  abdominal  ultrasonography
realised  for  abdominal  pain.  She  has  beneﬁted  from  a  regu-
lar  magnetic  resonance  imaging  (MRI)  follow-up  in  different
imaging  department.  Clinical  examination  and  liver  func-
tions  have  never  revealed  any  perturbation.
The  ﬁrst  (Fig.  1, line  A)  and  intermediate  (Fig.  1, line
B)  MRI,  which  were  respectively  performed  in  2006  andthe ﬁrst FNH (lesion 1), whereas the second one (lesion 2) increased sign
area, 45 mm diameter, associated with a focal capsular retraction, loca
other FNH (lesion 2) in segment IVA was continuing to increase to reach 
http://dx.doi.org/10.1016/j.diii.2014.11.004
2211-5684/© 2014 Published by Elsevier Masson SAS on behalf of the Édiiﬁcantly. Line C. Third MR examination (2014), exhibited a ﬁbrotic
ted in the segment IV, instead of the former FNH (lesion 1). The
26 mm.
tions françaises de radiologie.
32
(
h
o
o
A
a
d
m
A
w
1
c
d
4
t
F
G
w
w
b
e
m
D
F
c
r
h
F
0
f
O
e
t
[
s
f
r
n
a
s
l
B
a
e
r
h
C
F
a
•
•
•
D
T
c
t
c
d
m
w
a
c
R
[
[
[
[
[
[
[92  
009,  demonstrated  a  typical  focal  nodular  hyperplasia
FNH)  (lesion  1),  localized  in  segment  IV,  lobulated,  slightly
yperintense  on  T2-weighted  sequence,  slightly  hypointense
n  T1-weighted  sequence  and  with  marked  enhancement
n  arterial  phase  then  homogenization  without  washout.
 central  scar  was  observed  corresponding  to  a  central
rea  strongly  hyperintense  on  T2-weighted  sequence  with
elayed  enhancement.  Between  2006  and  2009,  its  maxi-
um  length  on  arterial  phase  reduced  from  56  mm  to  43  mm.
 second  typical  FNH  (lesion  2)  was  observed  in  segment  IV
hose  maximum  length  increased  from  11  mm  in  2006  to
6  mm  in  2009.
In  February  2014,  her  liver  MRI  was  performed  in  our
entre.  MR  examinations  (Fig.  1,  line  C)  exhibited  a  non-
ysmorphic,  non-fatty  liver,  and  identiﬁed  a  ﬁbrotic  area,
5  mm  diameter,  associated  with  a  focal  capsular  retrac-
ion,  located  in  the  segment  IV,  instead  of  the  former
NH  (lesion  1).  After  contrast  agent  injection  (Multihance®,
adobenatedimeglubine,  Bracco,  Milan,  Italy),  this  lesion
as  enhanced  only  at  delayed  phases  (2,  5  and  45  minutes),
hich  was  consistent  with  ﬁbrous  component.  At  hepato-
iliary  time  acquisition  (105  minutes),  the  lesion  showed  no
nhancement.  Interestingly,  the  other  FNH  (lesion  2)  in  seg-
ent  IVA  was  continuing  to  increase  to  reach  26  mm.
iscussion
NH  is  a  benign  proliferation  of  non-neoplastic  hepatocytes,
lassically  asymptomatic,  which,  when  typical,  does  not
equire  biopsy,  follow-up  or  treatment.  Different  evolutions
ave  been  described  in  various  proportions.  Most  of  time,
NH  remains  stable.  Proportion  of  growing  FNH  is  about
.7%  [2]  to  11.1%  [3].  Signiﬁcant  decreasing  in  length  ranges
rom  2.2%  [2]  to  55.5%  [3]  with  possible  disappearance.
ne  pathological  analysis  in  a  spontaneous  regression  case
xhibited  an  atypical  ﬁbrous  component  with  numerous  dys-
rophic  arteries.  Glutamine  synthetase  staining  was  negative
4].  MRI  demonstrated  a  loss  of  FNH  diagnosis  criteria  quite
imilar  to  our  case.  Two  factors  for  regression  have  been
ound:  older  age  and  long  follow-up  duration  [5]. Capsular
etraction  of  the  liver  is  classically  adjacent  to  a malig-
ant  hepatic  mass.  However,  this  phenomenon  was  observed
side  a  typical  FNH  [6].
In  this  observation,  for  the  last  follow-up,  the  lesion
howed  no  enhancement  at  hepatobiliary  phase  with
iver-speciﬁc  MRI  contrast  agents  (Gadobenatedimeglubine,
racco,  Milan,  Italy).  These  agents  may  help  to  differenti-
te  FNH  from  hepatocellular  adenoma  by  showing  the  biliary
xcretion  product  in  FNH  [1,7].  We  thought  that  the  total
egression  of  the  FNH  explains  the  lack  of  enhancement  at
epatobiliary  phase  due  to  the  lack  of  ductular  reaction.onclusion
inally,  this  case  illustrates  several  rare  ﬁndings  observed  in
 single  case  of  FNH:Letter  to  the  Editor
different  proﬁles  of  evolution  in  the  same  patient;
total  regression  of  the  typical  part  replaced  by  a  ﬁbrotic
area;
capsular  retraction  as  a  feature  of  ﬁbrosis  involvement  of
decreasing  FNH.
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